吉西他滨联合紫杉醇治疗晚期非小细胞肺癌的临床研究

目的探讨紫杉醇联合吉西他滨治疗晚期非小细胞肺癌(NSCLC)的近期疗效和安全性。方法老年晚期非小细胞肺癌92例,随机分为2组:吉西他滨1 000 mg联合紫杉醇120 mg方案(TG组)45例,吉西他滨联合卡铂方案(GC组)47例,每3~4周为l周期,连续用药3周期。结果近期疗效:2组组间总有效率(RR)及疾病控制率(DCR)经比较,差异无统计学意义;TG组中位生存期为8.6个月,3年生存率约6.6%;GC组中位生存期为9个月,3年生存率约6.4%;主要不良反应是Ⅲ~Ⅳ度骨髓抑制、血液学毒性、肝功能损害等,TG组血小板减少、白细胞减少以及贫血(Ⅲ~Ⅳ度)发生率明显少于GC组。结论吉西他滨联合紫杉醇治疗老年晚期NSCLC疗效较好,毒性反应较轻。

Clinical study of gemcitabine plus paclitaxel in the treatment of advanced non-small cell lung cancer

Objective To investigate the immediate efficacy and safety of paclitaxel plus gemcitabine in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Ninety-two elderly patients with NSCLC were randomly divided into two groups.The TG group(n=45) received 1000 mg paclitaxel combined with 120 mg gemcitabine,and the GC group(n=47) received gemcitabine combined with carboplatin(3 to 4 weeks for l-cycle,continuous medication for 3 cycles).Results Short-term effect: The total effectiveness rate between the 2 groups(RR) and disease control rate(DCR) after comparison showed that the difference was not statistically significant.TG group had a median survival of 8.6 months,and the 3-year survival rate was approximately 6.6%.GC group had a median survival of 9 months,and the 3-year survival rate was approximately 6.4%.Major adverse reactions included Ⅲ-Ⅳ myelosuppression,hematologic toxicity,liver dysfunction,the thrombocytopenia,leukopenia,and anemia(Ⅲ-Ⅳ degrees).But they were significantly less in TG group than in GC group.Conclusion The effect of gemcitabine in combination with paclitaxel in the treatment of elderly patients with advanced NSCLC is good with mild toxicity.